英国警告说,GLP-1药物有罕见的胰腺炎风险,报告病例超过1 100例,死亡17人。 UK warns of rare pancreatitis risk from GLP-1 drugs, with over 1,100 cases and 17 deaths reported.

英国的MHRA更新了对GLP-1药物 (如Wegovy,Ozempic和Mounjaro) 的指导,警告罕见但严重的急性胰腺炎风险,在2024年至2025年期间,英格兰,威尔士和苏格兰报告了超过1,100起相关病例,其中包括17起死亡. The UK's MHRA has updated its guidance on GLP-1 drugs like Wegovy, Ozempic, and Mounjaro, warning of a rare but serious risk of acute pancreatitis, with over 1,100 related cases reported in England, Wales, and Scotland between 2024 and 2025, including 17 fatalities. 虽然总体风险仍然很低,但该机构敦促患者在腹部或背部出现恶心或呕吐的严重疼痛时立即寻求医疗帮助,并通过黄卡计划报告副作用。 While the overall risk remains very low, the agency urges patients to seek immediate medical help for severe abdominal or back pain with nausea or vomiting, and to report side effects via the Yellow Card scheme. MAHRA还在研究遗传因素,以识别高风险个人。 The MHRA is also studying genetic factors to identify high-risk individuals.